Johnson & Johnson (NYSE:JNJ) Receives Buy Rating from Guggenheim

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reaffirmed by equities research analysts at Guggenheim in a research report issued on Friday,Benzinga reports. They presently have a $270.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 8.13% from the company’s previous close.

Several other research firms have also weighed in on JNJ. Bank of America upped their target price on Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a report on Friday, July 10th. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective on the stock in a research report on Wednesday, May 13th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a report on Monday. The Goldman Sachs Group restated a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday. Finally, Daiwa Securities Group increased their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research report on Thursday, April 16th. Nineteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $265.30.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $249.70 on Friday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a fifty-two week low of $162.30 and a fifty-two week high of $269.43. The firm’s fifty day simple moving average is $239.19 and its 200-day simple moving average is $234.50. The stock has a market cap of $601.08 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.34 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.86%. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same period in the prior year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts expect that Johnson & Johnson will post 11.67 earnings per share for the current fiscal year.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently added to or reduced their stakes in JNJ. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the period. State Street Corp increased its holdings in Johnson & Johnson by 1.3% in the 4th quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after purchasing an additional 1,663,782 shares in the last quarter. Auto Owners Insurance Co lifted its stake in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock worth $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Johnson & Johnson by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock valued at $11,967,947,000 after buying an additional 1,738,292 shares in the last quarter. Finally, Norges Bank purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $6,924,523,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson beat second-quarter estimates, with EPS of $2.90 and revenue of $25.31 billion, helped by strong growth in Innovative Medicine and products like Darzalex, Tremfya, and Spravato. Article Title
• Positive Sentiment: The company raised its full-year 2026 guidance after the beat, signaling management sees continued momentum beyond its legacy drugs and improving demand across its pharma and medtech businesses. Article Title
• Positive Sentiment: Analysts and market commentary point to growing confidence in J&J’s pipeline, with upbeat conference-call takeaways suggesting momentum could carry into 2027. Article Title
• Positive Sentiment: Spravato sales surged, which also supports the broader view that J&J has growth opportunities in newer therapeutic areas, not just its older blockbuster drugs. Article Title
• Neutral Sentiment: The company declared its quarterly dividend, reinforcing its defensive income appeal for long-term holders. Article Title
• Negative Sentiment: Despite the beat and guidance hike, shares sold off in early trading as investors appeared to focus on slower overall profit growth, a slight MedTech miss, and the market’s high bar for large-cap healthcare names. Article Title
• Negative Sentiment: Some investors remain cautious because talc litigation and mixed MedTech execution continue to create uncertainty around the stock’s risk/reward profile. Article Title

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.